Who is sponsoring NCT03457337?

NCT03457337 is sponsored by Henan Cancer Hospital.

What drugs are being tested in NCT03457337?

Interventions in NCT03457337: S-1 plus Gefitinib, Gefitinib.

What condition does NCT03457337 study?

NCT03457337 studies Advanced NSCLC With EGFR Mutation.

Is NCT03457337 still recruiting?

NCT03457337 is currently status unknown. Last updated 10 July 2020.

Last reviewed 2020-07-10 · How we verify

NCT03457337

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC

Status unknown Phase 2 Last updated 10 July 2020

What this trial tests

Phase 2 trial testing S-1 plus Gefitinib in Advanced NSCLC With EGFR Mutation in 200 participants. Status unknown.

Timeline

28 March 2018

Primary endpoint
31 October 2020

31 October 2021

Quick facts

Lead sponsor	Henan Cancer Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	200
Start date	28 March 2018
Primary completion	31 October 2020
Estimated completion	31 October 2021
Sites	1 location across China

Drugs / interventions tested

S-1 plus Gefitinib — full drug profile →
Gefitinib (gefitinib) — full drug profile →

Conditions studied

Advanced NSCLC With EGFR Mutation — all drugs for Advanced NSCLC With EGFR Mutation →

Sponsor

Henan Cancer Hospital

Who can join

Adults 18 to 75, any sex, with Advanced NSCLC With EGFR Mutation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To investigate the survival benefit of first-line therapy for patients with EGFR-sensitive mutation-positive advanced non-squamous non-small cell lung cancer treated with S-1plus gefitinib versus gefitinib monotherapy

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Henan Cancer Hospital trials

Trials by the same sponsor.

NCT07442890 — A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Ro · NA · not yet recruiting
NCT07472621 — Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma · not yet recruiting
NCT07459608 — Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma · Phase 2 · not yet recruiting
NCT07400575 — Anlotinib in Cross-line Treatment of NSCLC and SCLC · not yet recruiting
NCT07332221 — Application of Toripalimab as Adjuvant Therapy After Esophageal Cancer Surgery: A Multicenter Clinical Trial · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03457337 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Henan Cancer Hospital
Last refreshed: 10 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03457337.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing